122 related articles for article (PubMed ID: 28983609)
1. Molecular mechanisms of the inhibitory effects of jiangu granule‑containing serum on RANKL‑induced osteoclastogenesis.
Huang Y; Lin Y; Wu Y; Zeng J; Huang M; Guo S; Luo W; Lin H; Lin Y
Mol Med Rep; 2017 Dec; 16(6):8420-8426. PubMed ID: 28983609
[TBL] [Abstract][Full Text] [Related]
2. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH
Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149
[TBL] [Abstract][Full Text] [Related]
3. I‑BET151 inhibits osteoclastogenesis via the RANKL signaling pathway in RAW264.7 macrophages.
Cheng J; Zheng J; Guo N; Zi F
Mol Med Rep; 2017 Dec; 16(6):8406-8412. PubMed ID: 28983590
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.
Xu F; Dong Y; Huang X; Chen P; Guo F; Chen A; Huang S
Mol Med Rep; 2016 Sep; 14(3):2289-96. PubMed ID: 27430581
[TBL] [Abstract][Full Text] [Related]
5. Amiloride inhibits osteoclastogenesis by suppressing nuclear factor-κB and mitogen-activated protein kinase activity in receptor activator of nuclear factor-κB-induced RAW264.7 cells.
Wang X; Zhu Y; Zheng S; Ni C; Zhao L; Liu C; Chen A; Xiao J
Mol Med Rep; 2015 May; 11(5):3451-6. PubMed ID: 25592168
[TBL] [Abstract][Full Text] [Related]
6. The effects of Lycii Radicis Cortex on RANKL-induced osteoclast differentiation and activation in RAW 264.7 cells.
Kim JH; Kim EY; Lee B; Min JH; Song DU; Lim JM; Eom JW; Yeom M; Jung HS; Sohn Y
Int J Mol Med; 2016 Mar; 37(3):649-58. PubMed ID: 26848104
[TBL] [Abstract][Full Text] [Related]
7. Carnosol inhibits osteoclastogenesis
Cai P; Yan S; Lu Y; Zhou X; Wang X; Wang M; Yin Z
Mol Med Rep; 2022 Jul; 26(1):. PubMed ID: 35593299
[TBL] [Abstract][Full Text] [Related]
8. Low‑frequency pulsed electromagnetic field inhibits RANKL‑induced osteoclastic differentiation in RAW264.7 cells by scavenging reactive oxygen species.
Pi Y; Liang H; Yu Q; Yin Y; Xu H; Lei Y; Han Z; Tian J
Mol Med Rep; 2019 May; 19(5):4129-4136. PubMed ID: 30942408
[TBL] [Abstract][Full Text] [Related]
9. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
10. Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α.
Wang L; Qiu XM; Gui YY; Xu YP; Gober HJ; Li DJ
Drug Des Devel Ther; 2015; 9():3755-66. PubMed ID: 26229438
[TBL] [Abstract][Full Text] [Related]
11. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
12. Diarylheptanoid from Curcuma comosa Roxb. suppresses RANKL-induced osteoclast differentiation by decreasing NFATc1 and c-Fos expression via MAPK pathway.
Chawalitpong S; Sornkaew N; Suksamrarn A; Palaga T
Eur J Pharmacol; 2016 Oct; 788():351-359. PubMed ID: 27523282
[TBL] [Abstract][Full Text] [Related]
13. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
14. WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling.
Chen C; Qin Y; Fang JP; Ni XY; Yao J; Wang HY; Ding K
Acta Pharmacol Sin; 2015 Sep; 36(9):1053-64. PubMed ID: 26299951
[TBL] [Abstract][Full Text] [Related]
15. Crocin inhibits RANKL‑induced osteoclastogenesis by regulating JNK and NF‑κB signaling pathways.
Shi L; Zhao S; Chen Q; Wu Y; Zhang J; Li N
Mol Med Rep; 2018 Jun; 17(6):7947-7951. PubMed ID: 29620194
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
17.
Chen Y; Wei B; Xu P; Tang H; Yang L; Wang Y; Fu Y; Yang X; Mao Y
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576450
[TBL] [Abstract][Full Text] [Related]
18. Fructus Ligustri Lucidi ethanol extract inhibits osteoclastogenesis in RAW264.7 cells via the RANKL signaling pathway.
Xu D; Lyu Y; Chen X; Zhu X; Feng J; Xu Y
Mol Med Rep; 2016 Nov; 14(5):4767-4774. PubMed ID: 27748884
[TBL] [Abstract][Full Text] [Related]
19. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
20. Oleanolic acid inhibits RANKL-induced osteoclastogenesis via ER alpha/miR-503/RANK signaling pathway in RAW264.7 cells.
Xie BP; Shi LY; Li JP; Zeng Y; Liu W; Tang SY; Jia LJ; Zhang J; Gan GX
Biomed Pharmacother; 2019 Sep; 117():109045. PubMed ID: 31176167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
